[go: up one dir, main page]

EP1590345A1 - Xanthine derivatives as muscarinic receptor antagonists - Google Patents

Xanthine derivatives as muscarinic receptor antagonists

Info

Publication number
EP1590345A1
EP1590345A1 EP02808274A EP02808274A EP1590345A1 EP 1590345 A1 EP1590345 A1 EP 1590345A1 EP 02808274 A EP02808274 A EP 02808274A EP 02808274 A EP02808274 A EP 02808274A EP 1590345 A1 EP1590345 A1 EP 1590345A1
Authority
EP
European Patent Office
Prior art keywords
formula
compound
group
alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02808274A
Other languages
German (de)
French (fr)
Inventor
Anita Mehta
Sanjay Kumar Srivastava
Jang Bahadur Gupta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of EP1590345A1 publication Critical patent/EP1590345A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Definitions

  • This invention generally relates to derivatives of 3,6-disubstituted azabicyclo [3.1.0] hexanes.
  • the compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors.
  • the invention also relates to a process for the preparation of the compounds of the present invention, pharmaceutical compositions containing the compounds of the present invention and the methods for treating the diseases mediated through muscarinic receptors.
  • Muscarinic receptors as members of the G Protein Coupled Receptors are composed of a family of 5 receptor sub-types (Mi, M , M 3 , M 4 and M 5 ) and are activated by the neurotransmitter acetylcholine. These receptors are widely distributed on multiple organs and tissues and are critical to the maintenance of central and peripheral cholinergic neurotransmission. The regional distribution of these receptor sub-types in the brain and other organs has been documented.
  • the Mi subtype is located primarily in neuronal tissues such as cereberal cortex and autonomic ganglia
  • the M subtype is present mainly in the heart where it mediates chohnergically induced bradycardia
  • the M subtype is located predominantly on smooth muscle and salivary glands (Nature, 1986; 323: 411; Science, 1987; 237: 527).
  • Muscarinic agonists such as muscarine and pilocarpine and antagonists such as atropine have been known for over a century, but little progress has been made in the discovery of receptor subtype-selective compounds making it difficult to assign specific functions to the individual receptors.
  • classical muscarinic antagonists such as atropine are potent bronchodilators, their clinical utility is limited due to high incidence of both peripheral and central adverse effects such as tachycardia, blurred vision, dryness of mouth, constipation, dementia, etc.
  • the present invention provides 3,6-disubstituted azabicyclo[3.1.0]hexanes which function as muscarinic receptor antagonists which are useful as safe treatment of various diseases of the respiratory, urinary and gastrointestinal systems, and method for the synthesis of the compounds.
  • the invention also provides pharmaceutical compositions containing the compounds, and which may also contain acceptable carriers, excipients or diluents which are useful for the treatment of various diseases of respiratory, urinary and gastrointestinal systems.
  • the invention also includes the enantiomers, diastereomers, polymorphs, pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, N-oxides and metabolites of these compounds having the same type of activity.
  • the invention further includes pharmaceutical compositions comprising the compounds of the present invention, their enantiomers, diastereomers, polymorphs, pharmaceutically acceptable solvates, esters, N-oxides or metabolites, in combination with pharmaceutically acceptable carrier and optionally included excipients.
  • W represents (CH 2 ) P , where p represents 0 to 1;
  • X represents an oxygen, sulphur, -NR or no atom, wherein R represents hydrogen or
  • Y represents CHRiCO, wherein Ri represents hydrogen, methyl or (CH 2 )q wherein q represents 0 to 4; Z represents oxygen, sulphur, NR 2 , wherein R 2 represents hydrogen or C ⁇ - 6 alkyl; Q represents (CH 2 ) n , wherein n represents 0 to 4, or CHR 3 wherein R 3 represents H,
  • R 4 represents hydrogen, C 1 -C 15 saturated or unsarurated aliphatic hydrocarbon groups in which any 1 to 6 hydrogen atoms may be substituted with the group independently selected from halogen, arylalkyl, arylalkenyl, heteroarylalkyl or heteroarylalkenyl having 1 to 2 hetero atoms selected from the group consisting of nitrogen, oxygen and sulphur atoms with an option that any 1 to 3 hydrogen atoms on an aryl or heteroaryl ring in said arylalkyl, arylalkenyl, hetero arylalkenyl group may be substituted with lower alkyl (C1-C 4 ), lower perhalo alkyl (C ⁇ -C 4 ), cyano, hydroxyl, nitro, lower alkoxycarbonyl, halogen, lower alkoxy (C ⁇ -C 4 ), lower perhaloalkoxy (C ⁇ -C ), unsubstituted amino, N-lower alkylamino (C ⁇ -
  • Re and R 7 are independently selected from H, COOH, CH 3 , CONH 2 , NH 2 or CH 2 NH 2 ;
  • R 8 and R 9 are independently selected from a group consisting of lower alkyl (C ⁇ -C 4 ), trifluoromethyl, cyano, halogen, hydroxy, nitro, lower alkoxy (C ⁇ -C 4 ), amino or lower alkylamino.
  • a method for treatment or prophylaxis of an animal or a human suffering from a disease or disorder of the respiratory, urinary and gastrointestinal systems, wherein the disease or disorder is mediated through muscarinic receptors comprising administering to a patient in need thereof, an effective amount of compounds as described above.
  • a method for treatment or prophylaxis of an animal or a human suffering from a disease or disorder associated with muscarinic receptors comprising administering to a patient in need thereof, an effective amount of muscarinic receptor antagonist compounds as described above.
  • a method for treatment or prophylaxis of an animal or a human suffering from a disease or disorder of the respiratory systems such as bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary fibrosis, etc., urinary system which induce such urinary disorders as urinary incontinence, lower urinary tract systems (LUTS), etc., and gastrointestinal system such as irritable bowel syndrome, obesity, diabetes and gastrointestinal hyperkinesis with compound as described above, wherein the disease or disorder is associated with muscarinic receptors, comprising administering to a patient in need thereof, an effective amount of compounds as described above.
  • a disease or disorder of the respiratory systems such as bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary fibrosis, etc.
  • urinary system which induce such urinary disorders as urinary incontinence, lower urinary tract systems (LUTS), etc.
  • gastrointestinal system such as irritable bowel syndrome, obesity, diabetes and gastrointestinal hyperkinesis with compound as
  • the compounds of the present invention exhibit significant potency in terms of their activity, which was determined by in vitro receptor binding and functional assays and in vivo experiments using anaesthetised rabbit. Compounds were tested in vitro and in vivo. Some compounds were found to function as potent muscarinic receptor antagonists with high affinity towards M receptors. Therefore, the present invention provides pharmaceutical compositions for treatment of diseases or disorders associated with muscarinic receptors. Compounds and compositions described herein can be administered orally or parenterally.
  • the compounds described herein may be prepared by techniques well known in the art and familiar to the average synthetic organic chemist. In addition, the compounds described herein may be prepared by the following reaction sequence.
  • W represents (CH 2 ) P , where p represents 0 to 1;
  • X represents an oxygen, sulphur, - ⁇ R or no atom, wherein R represents hydrogen and
  • R 6 and R 7 are independently selected from H, COOH, CH 3 , CONH 2 , NH 2 or CH 2 NH 2 ;
  • R 8 and R 9 are independently selected from a group consisting of hydrogen, lower alkyl (C ⁇ -C ), trifluoromethyl, cyano, halogen, hydroxy, nitro, lower alkoxy (C ⁇ -C 4 ), amino or lower alkylamino; and
  • P is any group which can be used to protect an amino group in the presence of a condensing agent to give a protected compound of Formula V, which on deprotection through reaction with a deprotecting agent in an organic solvent gives an unprotected compound of Formula VI which is finally N-alkylated or benzylated with a suitable alkylating or benzylating agent L-R 4 to give a compound of Formula I wherein L is any leaving group;
  • R t represents hydrogen, C 1 -C 15 saturated or unsaturated aliphatic hydrocarbon groups in which any 1 to 6 hydrogen atoms may be substituted with the group independently selected from halogen, arylalkyl, arylalkenyl, heteroarylalkyl or heteroarylalkenyl having 1 to 2 hetero atoms selected from the group consisting of nitrogen, oxygen and sulphur atoms with an option that any 1 to 3 hydrogen atoms on an aryl or heteroaryl ring in said arylalkyl, arylalkenyl, hetero arylalkenyl group may be substituted with lower alkyl (C ⁇ -C 4 ), lower perhalo alkyl (C ⁇ -C 4 ), cyano, hydroxyl, nitro, lower alkoxycarbonyl, halogen, lower alkoxy (C ⁇ -C 4 ), lower perhaloalkoxy (C ⁇ -C 4 ), unsubstituted amino, N-lower alkylamino (C ⁇
  • P is any protecting group for an amino group for a compound of Formula VI and is selected from benzyl and t-butyloxy carbonyl groups.
  • reaction of the compound of Formula III with a compound of Formula IN to give a compound of Formula N can be carried out in presence of a condensing agent, for example, l-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (EDC) and 1, 8- diazabicyclo [5.4.0] undec-7ene (DBU).
  • a condensing agent for example, l-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (EDC) and 1, 8- diazabicyclo [5.4.0] undec-7ene (DBU).
  • reaction of the compound of Formula III with a compound of Formula IN to give a compound of Formula N can be carried out in a suitable solvent for example, ⁇ , ⁇ - dimethylformamide, dimethylsulfoxide, toluene and xylene at a temperature ranging from about 0 to about 140°C.
  • a suitable solvent for example, ⁇ , ⁇ - dimethylformamide, dimethylsulfoxide, toluene and xylene at a temperature ranging from about 0 to about 140°C.
  • NI can be carried out with a deprotecting agent, for example, palladium on carbon, trifluoroacetic acid (TFA) and hydrochloric acid.
  • a deprotecting agent for example, palladium on carbon, trifluoroacetic acid (TFA) and hydrochloric acid.
  • the deprotection of the compound of Formula N to give a compound of Formula NI can be carried out in a suitable organic solvent, for example, methanol, ethanol, tetrahydrofuran and acetonitrile at temperatures ranging from about 10 to about 50°C.
  • a suitable organic solvent for example, methanol, ethanol, tetrahydrofuran and acetonitrile at temperatures ranging from about 10 to about 50°C.
  • the ⁇ -alkylation or benzylation of the compound of Formula NI to give a compound of Formula I can be carried out with a suitable alkylating or benzylating agent, L- R 4 wherein L is any leaving group, known in the art, for example, halogen, O-mesityl and O-tosyl group.
  • the ⁇ -alkylation or benzylation of the compound of Formula NI to give a compound of Formula I can be carried out in a suitable organic solvent such as ⁇ , ⁇ - dimethylformamide, dimethylsulfoxide, tetrahydrofuran and acetonitrile, at temperatures ranging from about 25 to about 100°C. hi the above scheme, where specific bases, condensing agents, protecting groups, deprotecting agents, N-alkylating/benzylating agents, solvents, etc. are mentioned, it is to be understood that other bases, condensing agents, protecting groups, deprotecting agents, N-alkylating/benzylating agents, solvents, etc. known to those skilled in the art may be used. Similarly, the reaction temperature and duration may be adjusted according to the desired needs.
  • a suitable organic solvent such as ⁇ , ⁇ - dimethylformamide, dimethylsulfoxide, tetrahydrofuran and acetonitrile
  • Suitable salts of compounds represented by the Formula I were prepared so as to solubilize the compound in aqueous medium for biological evaluations.
  • examples of such salts are pharmacologically acceptable salts such as inorganic acid salts (e.g. hydrochloride, hydrobromide, sulphate, nitrate and phosphate), organic acid salts (e.g. acetate, tartarate, citrate, fumarate, maleate, toluenesulphonate and methanesulphonate).
  • inorganic acid salts e.g. hydrochloride, hydrobromide, sulphate, nitrate and phosphate
  • organic acid salts e.g. acetate, tartarate, citrate, fumarate, maleate, toluenesulphonate and methanesulphonate.
  • a carboxyl group When a carboxyl group is included in the Formula I as a substituent, it may be in its alkali metal salt form (e
  • compositions disclosed herein can be produced and admimstered in dosage units, each unit containing a certain amount of at least one compound described herein and/or at least one physiologically acceptable salt addition thereof.
  • the dosage may be varied over extremely wide limits as the compounds are effective at low dosage levels and relatively free of toxicity.
  • the compounds may be administered in the low micromolar concentration, which is therapeutically effective, and the dosage may be increased as desired up to the maximum dosage tolerated by the patient.
  • the present invention also includes the enantiomers, diastereomers, N-Oxides, polymorphs, solvates and pharmaceutically acceptable salts of these compounds as well as metabolites having the same type of activity.
  • the present invention further includes pharmaceutical composition comprising the molecules of Formula I and II, metabolites, enantiomers, diastereomers, N-oxides, polymorphs, solvates or pharmaceutically acceptable salts thereof, in combination with pharmaceutically acceptable carrier and optionally included excipients.
  • Various solvents such as acetone, methanol, pyridine, ether, tetrahydrofuran, hexanes, and dichloromethane were dried using various drying reagents according to procedures well known in the literature.
  • IR spectra were recorded as nujol mulls or a thin neat film on a Perkin Elmer Paragon instrument
  • Nuclear Magnetic Resonance (NMR) spectra were recorded on a Narian XL-300 MHz instrument using teframethylsilane as an internal standard.
  • 6-yl amide (3.00 mg, 1 eqv), as prepared in Example 1, was dissolved in methanol: tetrahydrofuran (80:20) (200 ml). To this reaction mixture, palladium on carbon was added and the resulting reaction mixture was stirred for 5 hours. To that mixture, acetic acid was added, followed by stirring for 4 hours. The organic compound xanthene-9- carboxylic acid-3-azabicyclo [3.1.0]-hex-6-yl amide was then filtered off and used as such without purification, which was dissolved in dimethylformamide, and potassium carbonate and potassium iodide were added. To this reaction mixture was added 4-cyano benzyl bromide and the reaction mixture was stirred overnight at room temperature.
  • reaction mixture was then stirred at room temperature.
  • the reaction mixture was diluted with water and then extracted the organic compound 9H-xanthene-9-carboxylic acid-(3 -benzyl)-3 -azabicyclo [3.1.0] -hex-6- yl] amide with ethyl acetate.
  • the purification was done by column chromatography using silica gel.
  • the reaction mixture was diluted with water and the organic compound (IR or IS) 9H-xanthene-9-carboxylic acid (3-benzyl)-3-azabicyclo[3.1.0]hex-6-yl- methyl] amide was extracted with ethyl acetate. Ethyl acetate was removed under reduced pressure and the residue dried under vacuuo. The purification was done by column chromatography using silica gel. Column was eluted with a mixture of ethyl acetate: hexane (5:95); (10:90); (15:85); (20:80); (30:70); (40-60) to yield 70 mg of the desired compound.
  • Example 5 Radioligand Binding Assays The affinity of test compounds for M 2 and M muscarinic receptor subtypes was determined by [ 3 H]-N-methylscopolamine binding studies using rat heart and submandibular gland respectively as described by Moriya et al., (Life Sci, 1999,64(25) :2351-2358) with minor modifications.
  • Membrane preparation Submandibular glands and heart were isolated and placed in ice cold homogenising buffer (HEPES 20mM, lOmM EDTA, pH 7.4) immediately after sacrifice. The tissues were homogenised in 10 volumes of homogenising buffer and the homogenate was filtered through two layers of wet gauze and filtrate was centrifuged at 500g for lOmin.
  • the supernatant was subsequently centrifuged at 40,000g for 20 min.
  • the pellet thus obtained was resuspended in assay buffer (HEPES 20 mM, EDTA 5mM, pH 7.4) and were stored at -70°C until the time of assay.
  • Ligand binding assay The compounds were dissolved and diluted in DMSO. The membrane homogenates (150-250 ⁇ g protein) were incubated in 250 ⁇ l of assay volume
  • Ki IC50 /(1+L/Kd), where L is the concentration of [ 3 H]NMS used in the particular experiment, pki is -log [Ki].

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention generally relates to the derivatives of 3,6 disubstituted azabicyclo[3.1.0] hexanes. The compounds of this invention can function as muscarinic receptor antagonists, inter alia for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to a process for the preparation of the compounds of the present invention, pharmaceutical compositions containing the compounds of the present invention and the methods for treating the diseases mediated through muscarinic receptors.

Description

XANTHINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS
FIELD OF THE INVENTION
This invention generally relates to derivatives of 3,6-disubstituted azabicyclo [3.1.0] hexanes.
The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors.
The invention also relates to a process for the preparation of the compounds of the present invention, pharmaceutical compositions containing the compounds of the present invention and the methods for treating the diseases mediated through muscarinic receptors.
BACKGROUND OF THE INVENTION
Muscarinic receptors as members of the G Protein Coupled Receptors (GPCRs) are composed of a family of 5 receptor sub-types (Mi, M , M3, M4 and M5) and are activated by the neurotransmitter acetylcholine. These receptors are widely distributed on multiple organs and tissues and are critical to the maintenance of central and peripheral cholinergic neurotransmission. The regional distribution of these receptor sub-types in the brain and other organs has been documented. For example, the Mi subtype is located primarily in neuronal tissues such as cereberal cortex and autonomic ganglia, the M subtype is present mainly in the heart where it mediates chohnergically induced bradycardia, and the M subtype is located predominantly on smooth muscle and salivary glands (Nature, 1986; 323: 411; Science, 1987; 237: 527).
A review in Current Opinions in Chemical Biology, 1999; 3: 426, as well as in
Trends in Pharmacological Sciences, 2001; 22: 409 by Eglen et. al., describe the biological potentials of modulating muscarinic receptor subtypes by ligands in different disease conditions like Alzheimer's disease, pain, urinary disease condition, chronic obstructive pulmonary disease etc.
A review in J. Med. Chem.. 2000; 43: 4333 by Christian C. Felder et. al. describes therapeutic opportunities for muscarinic receptors in the central nervous system and
1 elaborates on muscarinic receptor structure and function, pharmacology and their therapeutic uses.
The pharmacological and medical aspects of the muscarinic class of acetylcholine agonists and antagonists are presented in a review in Molecules, 2001, 6: 142.
N.J.M. Birdsall et. al. in Trends in Pharmacological Sciences, 2001; 22: 215 have also summarized the recent developments on the role of different muscarinic receptor subtypes using different muscaranic receptors of knock out mice.
Muscarinic agonists such as muscarine and pilocarpine and antagonists such as atropine have been known for over a century, but little progress has been made in the discovery of receptor subtype-selective compounds making it difficult to assign specific functions to the individual receptors. Although classical muscarinic antagonists such as atropine are potent bronchodilators, their clinical utility is limited due to high incidence of both peripheral and central adverse effects such as tachycardia, blurred vision, dryness of mouth, constipation, dementia, etc. Subsequent development of the quarterly derivatives of atropine such as ipratropium bromide are better tolerated than parenterally administered options but most of them are not ideal anti-cholinergic bronchodilators due to lack of selectivity for muscarinic receptor sub-types. The existing compounds offer limited therapeutic benefit due to their lack of selectivity resulting in dose limiting side-effects such as thirst, nausea, mydriasis and those associated with the heart such as tachycardia mediated by the M2 receptor.
Annual review of Pharmacological Toxicol., 2001; 41: 691, describes the pharmacology of the lower urinary tract infections. Although anti muscarinic agents such as oxybutynin and tolterodine that act non-selectively on muscarinic receptors have been used for many years to treat bladder hyperactivity, the clinical effectiveness of these agents has been limited due to the side effects such as dry mouth, blurred vision and constipation. Tolterodine is considered to be generally better tolerated than oxybutynin. (W.D.Steers et. al. in Curr. Opin. Invest. Drugs, 2: 268, CR. Chappie et. al. in Urology, 55: 33), Steers WD, Barrot DM, Wein AJ, 1996, Voiding dysfunction: diagnosis classification and management. In "Adult and Pediatric Urology," ed. JY Gillenwatter, JT Grayhack, SS Howards, JW Duckett, pp 1220-1325, St. Louis, MO; Mosby. 3rd edition.) Despite these advances, there remains a need for development of new highly selective muscarinic antagonists which can interact with distinct subtypes, thus avoiding the occurrence of adverse effects.
Compounds having antagonistic activity against muscarinic receptors have been described in Japanese patent application Laid Open Number 92921/1994 and 135958/1994; WO 93/16048; U.S. Patent No. 3,176,019; GB 940,540; EP 0325 571; WO 98/29402; EP 0801067; EP 0388054; WO 9109013; U.S. Patent No. 5,281,601. U.S. Patent Nos. 6,174,900, 6,130,232 and 5,948,792; WO 97/45414 are related to 1,4-disubstituted piperidine derivatives; WO 98/05641 describes fluorinated, 1 ,4-disubstitued piperidine derivatives; WO 93/16018 and WO96/33973 are other close art references.
A report in J. Med. Chem., 2002; 44:984, describes cyclohexylmethyl piperidinyl triphenylpropioamide derivatives as selective M3 antagonist discriminating against the other receptor subtypes.
SUMMARY OF THE INVENTION
The present invention provides 3,6-disubstituted azabicyclo[3.1.0]hexanes which function as muscarinic receptor antagonists which are useful as safe treatment of various diseases of the respiratory, urinary and gastrointestinal systems, and method for the synthesis of the compounds.
The invention also provides pharmaceutical compositions containing the compounds, and which may also contain acceptable carriers, excipients or diluents which are useful for the treatment of various diseases of respiratory, urinary and gastrointestinal systems.
The invention also includes the enantiomers, diastereomers, polymorphs, pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, N-oxides and metabolites of these compounds having the same type of activity.
The invention further includes pharmaceutical compositions comprising the compounds of the present invention, their enantiomers, diastereomers, polymorphs, pharmaceutically acceptable solvates, esters, N-oxides or metabolites, in combination with pharmaceutically acceptable carrier and optionally included excipients.
Other advantages of the invention will be set forth in the description which follows and in part will be apparent from the description or may be learnt by the practice of the invention. The objects and the advantages of the invention may be realized and obtained by means of the mechanisms and combinations pointed out in the appended claims.
In accordance with one aspect of the present invention, there is provided a compound having the structure of Formula I:
Formula I
and its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs, or metabolites, wherein W represents (CH2)P, where p represents 0 to 1; X represents an oxygen, sulphur, -NR or no atom, wherein R represents hydrogen or
Cι-6 alkyl; Y represents CHRiCO, wherein Ri represents hydrogen, methyl or (CH2)q wherein q represents 0 to 4; Z represents oxygen, sulphur, NR2, wherein R2 represents hydrogen or Cι-6 alkyl; Q represents (CH2)n, wherein n represents 0 to 4, or CHR3 wherein R3 represents H,
OH, Cι-6 alkyl, Cι-6 alkenyl, Cι-6 alkoxy or CH2CHR5 wherein R5 represents H,
OH, lower alkyl (Cι-C ) or lower alkoxy (Cι-C4);
R4 represents hydrogen, C1-C15 saturated or unsarurated aliphatic hydrocarbon groups in which any 1 to 6 hydrogen atoms may be substituted with the group independently selected from halogen, arylalkyl, arylalkenyl, heteroarylalkyl or heteroarylalkenyl having 1 to 2 hetero atoms selected from the group consisting of nitrogen, oxygen and sulphur atoms with an option that any 1 to 3 hydrogen atoms on an aryl or heteroaryl ring in said arylalkyl, arylalkenyl, hetero arylalkenyl group may be substituted with lower alkyl (C1-C4), lower perhalo alkyl (Cι-C4), cyano, hydroxyl, nitro, lower alkoxycarbonyl, halogen, lower alkoxy (Cι-C4), lower perhaloalkoxy (Cι-C ), unsubstituted amino, N-lower alkylamino (Cι-C4) or N- lower alkylamino carbonyl (Cι-C ) N,N-lower dialkylamino (Cι-C4); N,N-lower dialkylamino carbonyl (Cι-C4).
Re and R7 are independently selected from H, COOH, CH3, CONH2, NH2 or CH2NH2; and
R8 and R9 are independently selected from a group consisting of lower alkyl (Cι-C4), trifluoromethyl, cyano, halogen, hydroxy, nitro, lower alkoxy (Cι-C4), amino or lower alkylamino.
In accordance with a second aspect of the present invention there is provided a compound having the structure of Formula II and its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs, metabolites, wherein W, X, Y, Z, Q, R-t, R8 and R9 are the same as defined for Formula I.
Formula II
In accordance with a third aspect of the present invention, there is provided a method for treatment or prophylaxis of an animal or a human suffering from a disease or disorder of the respiratory, urinary and gastrointestinal systems, wherein the disease or disorder is mediated through muscarinic receptors comprising administering to a patient in need thereof, an effective amount of compounds as described above.
In accordance with a fourth aspect of the present invention, there is provided a method for treatment or prophylaxis of an animal or a human suffering from a disease or disorder associated with muscarinic receptors, comprising administering to a patient in need thereof, an effective amount of muscarinic receptor antagonist compounds as described above. In accordance with a fifth aspect of the present invention, there is provided a method for treatment or prophylaxis of an animal or a human suffering from a disease or disorder of the respiratory systems such as bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary fibrosis, etc., urinary system which induce such urinary disorders as urinary incontinence, lower urinary tract systems (LUTS), etc., and gastrointestinal system such as irritable bowel syndrome, obesity, diabetes and gastrointestinal hyperkinesis with compound as described above, wherein the disease or disorder is associated with muscarinic receptors, comprising administering to a patient in need thereof, an effective amount of compounds as described above.
In accordance with a sixth aspect of the present invention, there is provided process for preparing the compounds as described above.
The compounds of the present invention exhibit significant potency in terms of their activity, which was determined by in vitro receptor binding and functional assays and in vivo experiments using anaesthetised rabbit. Compounds were tested in vitro and in vivo. Some compounds were found to function as potent muscarinic receptor antagonists with high affinity towards M receptors. Therefore, the present invention provides pharmaceutical compositions for treatment of diseases or disorders associated with muscarinic receptors. Compounds and compositions described herein can be administered orally or parenterally.
DETAILED DESCRIPTION OF THE INVENTION
The compounds described herein may be prepared by techniques well known in the art and familiar to the average synthetic organic chemist. In addition, the compounds described herein may be prepared by the following reaction sequence.
Scheme-I
Formula III Formula IV
Condensing agent
Formula V
L-R4 N-Alkylation/N-Benzylation
Formula I
Although Formula I is shown with a particular stereochemical configuration, the invention is by no means limited to the production or use of compounds of a particular stereochemistry. Those of ordinary skill in the art will recognize methods for the production of compounds other than those depicted in particular Schemes or Examples, and which are within the scope of the appended claims. The compounds of Formula I of the present invention may be prepared by the reaction sequence as shown in Scheme I. The preparation comprises condensing a compound of Formula III with the compound of Formula IN wherein
W represents (CH2)P, where p represents 0 to 1;
X represents an oxygen, sulphur, -ΝR or no atom, wherein R represents hydrogen and
Ci-e alkyl; Y represents CHRiCO, wherein Ri represents hydrogen, methyl or (CH2)q wherein q represents 0 to 4; Z represents oxygen, sulphur, ΝR2, wherein R represents hydrogen or Cι-6 alkyl; Q represents (CH2)n, wherein n represents 0 to 4, or CHR3 wherein R represents H,
OH, Cι-6 alkyl, Cι-6 alkenyl, Cι-6 alkoxy or CH2CHR5 wherein R5 represents H,
OH, lower alkyl (Cι-C4) or lower alkoxy (Cι-C4);
R6 and R7 are independently selected from H, COOH, CH3, CONH2, NH2 or CH2NH2;
R8 and R9 are independently selected from a group consisting of hydrogen, lower alkyl (Cι-C ), trifluoromethyl, cyano, halogen, hydroxy, nitro, lower alkoxy (Cι-C4), amino or lower alkylamino; and
P is any group which can be used to protect an amino group in the presence of a condensing agent to give a protected compound of Formula V, which on deprotection through reaction with a deprotecting agent in an organic solvent gives an unprotected compound of Formula VI which is finally N-alkylated or benzylated with a suitable alkylating or benzylating agent L-R4 to give a compound of Formula I wherein L is any leaving group;
Rt represents hydrogen, C1-C15 saturated or unsaturated aliphatic hydrocarbon groups in which any 1 to 6 hydrogen atoms may be substituted with the group independently selected from halogen, arylalkyl, arylalkenyl, heteroarylalkyl or heteroarylalkenyl having 1 to 2 hetero atoms selected from the group consisting of nitrogen, oxygen and sulphur atoms with an option that any 1 to 3 hydrogen atoms on an aryl or heteroaryl ring in said arylalkyl, arylalkenyl, hetero arylalkenyl group may be substituted with lower alkyl (Cι-C4), lower perhalo alkyl (Cι-C4), cyano, hydroxyl, nitro, lower alkoxycarbonyl, halogen, lower alkoxy (Cι-C4), lower perhaloalkoxy (Cι-C4), unsubstituted amino, N-lower alkylamino (Cι-C4) or N- lower alkylamino carbonyl (Cι-C4) N,N-lower dialkylamino (Cι-C4); N,N-lower dialkylamino carbonyl (Cι-C4).
P is any protecting group for an amino group for a compound of Formula VI and is selected from benzyl and t-butyloxy carbonyl groups.
The reaction of the compound of Formula III with a compound of Formula IN to give a compound of Formula N can be carried out in presence of a condensing agent, for example, l-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (EDC) and 1, 8- diazabicyclo [5.4.0] undec-7ene (DBU).
The reaction of the compound of Formula III with a compound of Formula IN to give a compound of Formula N can be carried out in a suitable solvent for example, Ν, Ν- dimethylformamide, dimethylsulfoxide, toluene and xylene at a temperature ranging from about 0 to about 140°C.
The deprotection of the compound of Formula N to give a compound of Formula
NI can be carried out with a deprotecting agent, for example, palladium on carbon, trifluoroacetic acid (TFA) and hydrochloric acid.
The deprotection of the compound of Formula N to give a compound of Formula NI can be carried out in a suitable organic solvent, for example, methanol, ethanol, tetrahydrofuran and acetonitrile at temperatures ranging from about 10 to about 50°C.
The Ν-alkylation or benzylation of the compound of Formula NI to give a compound of Formula I can be carried out with a suitable alkylating or benzylating agent, L- R4 wherein L is any leaving group, known in the art, for example, halogen, O-mesityl and O-tosyl group.
The Ν-alkylation or benzylation of the compound of Formula NI to give a compound of Formula I can be carried out in a suitable organic solvent such as Ν, Ν- dimethylformamide, dimethylsulfoxide, tetrahydrofuran and acetonitrile, at temperatures ranging from about 25 to about 100°C. hi the above scheme, where specific bases, condensing agents, protecting groups, deprotecting agents, N-alkylating/benzylating agents, solvents, etc. are mentioned, it is to be understood that other bases, condensing agents, protecting groups, deprotecting agents, N-alkylating/benzylating agents, solvents, etc. known to those skilled in the art may be used. Similarly, the reaction temperature and duration may be adjusted according to the desired needs.
Suitable salts of compounds represented by the Formula I were prepared so as to solubilize the compound in aqueous medium for biological evaluations. Examples of such salts are pharmacologically acceptable salts such as inorganic acid salts (e.g. hydrochloride, hydrobromide, sulphate, nitrate and phosphate), organic acid salts (e.g. acetate, tartarate, citrate, fumarate, maleate, toluenesulphonate and methanesulphonate). When a carboxyl group is included in the Formula I as a substituent, it may be in its alkali metal salt form (e.g. sodium, potassium, calcium, magnesium, and the like). These salts may be prepared by the usual prior art techniques, such as treating the compound with an equivalent amount of inorganic or organic, acid or base in a suitable solvent.
Particular compounds which are capable of being produced by the Scheme I include:
Compound No. Chemical Name
1. 9H-Xanthene-9-carboxylic acid-[(3-benzyl)-3-azabicyclo[3.1.0]-hex-6-yl] amide (Compound No. 1) 2. 9H-Xanthene-9-carboxylic acid-[3-(4-cyanobenzyl)-3-azabicyclo[3.1.0]-hex-6-yl] amide (Compound No. 2)
3. 9H-Xanthene-9-carboxylic acid-[(3-benzyl)-3-azabicyclo[3.1.0]-hex-6-yl-methyl] amide (Compound No.3)
4. 9H-Xanthene-9-carboxylic acid- [(3 -benzyl)-3 -azabicyclo [3.1.0] -hex- 1 -yl-methyl] - amide (Compound No. 4)
Compounds or compositions may be administered to an animal for treatment orally, or by a parenteral route. Pharmaceutical compositions disclosed herein can be produced and admimstered in dosage units, each unit containing a certain amount of at least one compound described herein and/or at least one physiologically acceptable salt addition thereof. The dosage may be varied over extremely wide limits as the compounds are effective at low dosage levels and relatively free of toxicity. The compounds may be administered in the low micromolar concentration, which is therapeutically effective, and the dosage may be increased as desired up to the maximum dosage tolerated by the patient.
The present invention also includes the enantiomers, diastereomers, N-Oxides, polymorphs, solvates and pharmaceutically acceptable salts of these compounds as well as metabolites having the same type of activity. The present invention further includes pharmaceutical composition comprising the molecules of Formula I and II, metabolites, enantiomers, diastereomers, N-oxides, polymorphs, solvates or pharmaceutically acceptable salts thereof, in combination with pharmaceutically acceptable carrier and optionally included excipients.
The examples mentioned below demonstrate the general synthetic procedure as well as the specific preparation of the preferred compound. The examples are provided to illustrate particular aspects of the disclosure should not be constrained to limit the scope of the present invention, as defined by the claims.
EXPERIMENTAL DETAILS
Various solvents, such as acetone, methanol, pyridine, ether, tetrahydrofuran, hexanes, and dichloromethane were dried using various drying reagents according to procedures well known in the literature. IR spectra were recorded as nujol mulls or a thin neat film on a Perkin Elmer Paragon instrument, Nuclear Magnetic Resonance (NMR) spectra were recorded on a Narian XL-300 MHz instrument using teframethylsilane as an internal standard.
Example 1: Preparation of 9H-Xanthene-9-carboxylic acid-[(3-benzyl)-3-azabicyclo [3.1.0]-hex-6-yI amide (Compound No. 1)
A solution of Xanthene-9-carboxylic acid (Lancaster Synthesis, Windham NH) (0.25g, 1 eqv) and N-3-benzyl-3-azabicyclo [3.1.0] hex-6-yl-amine (0.31 g, 1.5 eqv)
(procedure of T.F. Braish et. al., Synlett, 1996, 1100) in dimethylformamide was cooled to 0°C. Butanol was then added followed by the addition of N-methyl morpholine (NMM). The reaction mixture was stirred for 30 minutes at 0°C. l-(3-dimethylaminopropyl)-3- ethyl carbodiimide hydrochloride (EDC) was then added and the reaction mixture was again stirred for 3 hr at 0°C. It was then allowed to stir at room temperature and the organic compound 9H-xanthene-9-carboxylic acid-(3-benzyl)-3-azabicyclo[3.1.0]-hex-6- yl]-amide (0.35g) was extracted with dichloromethane. The solvent dichloromethane was evaporated under reduced pressure and dried under vacuuo. The organic compound was purified by column chromatography. The melting point was 217-219°C; 1HNMR (CDC ): 7.39-7.32 (m, 2H), 7.30-7.07 (m, 1 IH), 5.20 (bs, IH), 4.85 (s, 2H), 3.02-2.93 (m, 3H), 2.29 (d, 2H, J=6Hz), 1.28-1.26 (m, 2H); mass (m/z): 397; IR (KBR): 3296, 2788, 1684 cm"1 .
Example 2: Preparation of 9H-Xanthene-9-carboxylic acid-[3~(4-cyano-benzyl)~3- azabicyclo[3.1.0]-hex-6~yl]amide (Compound No. 2)
The compound 9H-xanthene-9-carboxylic acid-(3-benzyl-3-azabicyclo [3.1.0]hex-
6-yl amide (3.00 mg, 1 eqv), as prepared in Example 1, was dissolved in methanol: tetrahydrofuran (80:20) (200 ml). To this reaction mixture, palladium on carbon was added and the resulting reaction mixture was stirred for 5 hours. To that mixture, acetic acid was added, followed by stirring for 4 hours. The organic compound xanthene-9- carboxylic acid-3-azabicyclo [3.1.0]-hex-6-yl amide was then filtered off and used as such without purification, which was dissolved in dimethylformamide, and potassium carbonate and potassium iodide were added. To this reaction mixture was added 4-cyano benzyl bromide and the reaction mixture was stirred overnight at room temperature. It was then diluted with water and the organic compound 9H-Xanthene-9-carboxylic-[4-(4- cyanobenzyl)-3-azabicyclo [3.1.0]-hex-6-yl-amide was extracted with ethylacetate.
Purification of this compound was done by column chromatography using silica gel (100- 200 mesh). Column was eluted with (ethyl acetate : hexane) : (50 :50), (70 :30), (85 :15) to yield 150 mg of the desired compound. The melting point was 201-202°C; 1HNMR (CDC13): 7.53 (d, 2H, J=8.1 Hz), 7.38-7.26 (m, 6H), 7.13-7.08 (m, 4H), 5.21 (bs, IH), 4.85 (s, IH), 3.54 (s, 2H), 3.00 (d, 2H, J=8.7 Hz), 2.91 (s, IH), 2.31 (d, 2H, J=8.7 Hz), 1.31- 1.25 (m, 2H); Mass (m/z) 422; IR (KBr): 3240, 2783, 2227, 1640 cm4.
Example 3: Preparation of 9H-Xanthene-9-carboxylic acid-[(3-benzyl)-3- azabicyclo[3.1.0]-hex-6-yl]-methyl] amide (Compound No.3)
A solution of xanthene-9-carboxylic acid (Lancaster) (0.25 g, 1 eqv.) and N-3- benzyl-3-azabicyclo [3.1.0] hex-6-yl-methyl amine (procedure of EP 0,413,455 A2) in dimethylformamide were taken and cooled to 0°C. Butanol and N-methyl morpholine (NMM) were also added subsequently. The solution was allowed to stir for 30 minutes at 0°C. l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) was then added and the stirring was continued for 3 hr at 0°C. The reaction mixture was then stirred at room temperature. The reaction mixture was diluted with water and then extracted the organic compound 9H-xanthene-9-carboxylic acid-(3 -benzyl)-3 -azabicyclo [3.1.0] -hex-6- yl] amide with ethyl acetate. Evaporated ethyl acetate under reduced pressure and dried under vacuuo. The purification was done by column chromatography using silica gel. Column was eluted with a mixture of ethyl acetate : hexane (10:90); Ethyl acetate : hexane (20:80); Ethyl acetate : Hexane (30:70); Ethyl acetate : Hexane (50:50); Ethyl Acetate : Hexane (65:25) to yield 80 mg of the desired product. The melting point was 181-183°C; !HNMR (CDC13) δ: 7.39 (d, 2H, J=7.6 Hz), 7.31-7.09 (m, 11H), 5.27 (bs, IH), 4.87 (s, IH), 3.52 (s, 2H), 3.00-2.95 (m, 2H), 2.80 (d, 2H, J=8.5 Hz), 2.23 (d, 2H, J=8.6 Hz), 1.25- 1.19 (m, IH), 1.10 (m, 2H); Mass. (m z): 411.2.
Example 4: Preparation of 9H-Xanthene-9-carboxylic acid-[(3-benzy)-3- azabicyclo[3.1.0]-hex-l-yl-methyl]amide (Compound No. 4)
A solution of xanthene-9-carboxylic acid (Lancaster) (0.25 g, 1 eqv.) and N-3- benzyl-3-azabicyclo [3.1.0]hex-l-yl methylamine (procedure of EP 0,413, 455 A2) in dimethylformamide was cooled at 0°C. Butanol and N-methyl morpholine (NMM) were also added subsequently. The solution was allowed to stir for 30 minutes at 0°C. l-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) was then added and the stirring was continued for 3 hr at 0°C. The reaction mixture was then stirred at room temperature. The reaction mixture was diluted with water and the organic compound (IR or IS) 9H-xanthene-9-carboxylic acid (3-benzyl)-3-azabicyclo[3.1.0]hex-6-yl- methyl] amide was extracted with ethyl acetate. Ethyl acetate was removed under reduced pressure and the residue dried under vacuuo. The purification was done by column chromatography using silica gel. Column was eluted with a mixture of ethyl acetate: hexane (5:95); (10:90); (15:85); (20:80); (30:70); (40-60) to yield 70 mg of the desired compound. The melting point was 186-188°C; 1HNMR (CDC13) δ: 7.06-7.39 (m, 13H), 5.26 (bs, IH), 4.87 (s, IH), 3.44 (dd, 2H, J=5.7 MHz), 3.19-3.25 (m, 2H), 2.78-2.81 (m, IH), 2.63-2.66 (m, IH), 2.10-2.14 (m, IH), 1.93-1.96 (m, IH), 1.00-1.03 (m, IH), 0.90 (m, IH), 0.19-0.23 (m, IH); Mass. :m/z=411.3.
Example 5: Radioligand Binding Assays The affinity of test compounds for M2 and M muscarinic receptor subtypes was determined by [3H]-N-methylscopolamine binding studies using rat heart and submandibular gland respectively as described by Moriya et al., (Life Sci, 1999,64(25) :2351-2358) with minor modifications. Membrane preparation: Submandibular glands and heart were isolated and placed in ice cold homogenising buffer (HEPES 20mM, lOmM EDTA, pH 7.4) immediately after sacrifice. The tissues were homogenised in 10 volumes of homogenising buffer and the homogenate was filtered through two layers of wet gauze and filtrate was centrifuged at 500g for lOmin. The supernatant was subsequently centrifuged at 40,000g for 20 min. The pellet thus obtained was resuspended in assay buffer (HEPES 20 mM, EDTA 5mM, pH 7.4) and were stored at -70°C until the time of assay.
Ligand binding assay: The compounds were dissolved and diluted in DMSO. The membrane homogenates (150-250 μg protein) were incubated in 250 μl of assay volume
(HEPES 20 mM, pH 7.4) at 24-25°C for 3h. Non-specific binding was determined in the presence of 1 μM atropine . The incubation was terminated by vacuum filtration over GF/B fiber filters(Wallac). The filters were then washed with ice cold 50mM Tris HC1 buffer (pH 7.4). The filter mats were dried and bound radioactivity retained on filters was counted. The IC50 & Kd were estimated by using the non-linear curve fitting program using G Pad Prism software. The value of inhibition constant Ki was calculated from competitive binding studies by using Cheng & Prusoff equation (Biochem Pharmacol.,
(1973), 22: 3099-3108), Ki = IC50 /(1+L/Kd), where L is the concentration of [3H]NMS used in the particular experiment, pki is -log [Ki].
Functional Experiments using isolated rat bladder: Animals were euthanized by overdose of thiopentone and whole bladder was isolated and removed rapidly and placed in ice cold Tyrode buffer with the following composition (mMol/L) NaCl 137; KCl 2.7; CaCl2 1.8; MgCl2 0.1; NaHCO3 11.9; NaH2PO4 0.4; Glucose 5.55 and continuously gassed with 95% O and 5 % CO2. The bladder was cut into longitudinal strips (3mm wide and 5-6 mm long) and mounted in 10 ml organ baths at 30° C, with one end connected to the base of the tissue holder and the other end connected through a force displacement transducer. Each tissue was maintained at a constant basal tension of 1 g and
1 /9 allowed to equilibrate for 1 hour during which the Tyrode buffer was changed every 15- 20 min. At the end of equilibration period the stabilization of the tissue contractile response was assessed with lμmol/L of Carbachol till a reproducible response is obtained. Subsequently a cumulative concentration response curve to carbachol (10"9 mol/L to 3 X 10" mol/L) was obtained. After several washes, once the baseline was achieved, cumulative concentration response curve was obtained in presence of NCE (NCE added 20 min. prior to the second cumulative response curve.
The contractile results were expressed as % of control E max. ED50 values were calculated by fitting a non-linear regression curve (Graph Pad Prism). pKb values were calculated by the formula pKb = - log [ (molar concentration of antagonist/ (dose ratio- 1))] where, dose ratio = ED50 in the presence of antagonist/ED50 in the absence of antagonist. The results of in- vitro tests are listed in Table I.
Table I
While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.

Claims

WE CLAIM:
1. A compound having the structure of Formula I
Formula I
and its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs, metabolites, wherein:
W represents (CH2)P, where p represents 0 to 1;
X represents an oxygen, sulphur, -NR or no atom, wherein R represent
hydrogen or Cι-6 alkyl;
Y represents CHRiCO, wherein Ri represents hydrogen or methyl or (CH2)q wherein q represents 0 to 4;
Z represents oxygen, sulphur, NR , wherein R2 represents hydrogen or Cι-6 alkyl;
Q represents (CH2)n wherein n represents 0 to 4, or CHR3 wherein R3 represents H, OH, Cι-6 alkyl, Cι-6 alkenyl, Cι-6 alkoxy or CH2CHR5 wherein R5 represents H, OH, lower alkyl (Cι-C ) or lower alkoxy (Cι-C4);
R4 represents hydrogen, C1-C15 saturated or unsaturated aliphatic hydrocarbon groups in which any 1 to 6 hydrogen atoms may be substituted with the group independently selected from halogen, arylalkyl, arylalkenyl, heteroarylalkyl or heteroarylalkenyl having 1 to 2 hetero atoms selected from a group consisting of nitrogen, oxygen and sulphur atoms with option that any 1 to 3 hydrogen atoms on the ring in said arylalkyl, arylalkenyl, hetero arylalkenyl group may be substituted with lower alkyl (Cι-C4), lower perhalo alkyl (Cι-C4), cyano, hydroxyl, nitro, lower alkoxycarbonyl, halogen, lower alkoxy (Cι-C4), lower perhaloalkoxy (Cι-C4), unsubstituted amino, N-lower alkylamino (Cι-C ) or N- lower alkylamino carbonyl (Cι-C4);
Re and R7 are independently selected from H, COOH, CH3, CONH2, NH2 or CH2NH2; and
R8 and R9 are independently selected from a group consisting of hydrogen, lower alkyl (Cι-C4), trifluoromethyl, cyano, halogen, hydroxy, nitro, lower alkoxy (Cι-C4), amino or lower alkylamino.
2. The compound according to claim 1 having the structure of Formula II and its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs, metabolites wherein R8, R9, R4, W, X, Y, Z, Q are the same as defined for Formula I
Formula II
3. A compound selected from the group consisting of
9H-Xanthene-9-carboxylic acid-(3-benzyl)-3-azabicyclo[3.1.0]-hex-6-yl]amide;
9H-Xanthene-9-carboxylic acid-[3-(4-cyanobenzyl)-3-azabicyclo[3.1.0]-hex-6-yl] amide;
9H-Xanthene-9-carboxylic acid-[(3-benzyl)-3-azabicyclo[3.1.0]-hex-6-yl-methyl] amide; and
9H-Xanthene-9-carboxylic acid-[(3-benzyl)-3-azabicyclo[3.1.0]-hex-l-yl-methyl]- amide.
4. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound as defined in claim 1, 2 or 3 together with pharmaceutically acceptable carriers, excipients or diluents. A method for treatment or prophylaxis of an animal or a human suffering from a disease or disorder of the respiratory, urinary and gastrointestinal systems, wherein the disease or disorder is mediated through the muscarinic receptors, comprising administering to said animal or human, a therapeutically effective amount of a compound having the structure of Formula I,
Formula I or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs, metabolites, wherein;
W represents (CH2)P, where p represents 0 to 1;
X represents an oxygen, sulphur, -NR or no atom, wherein R represents hydrogen or Cι-6 alkyl; Y represents CHRiCO, wherein Ri represents hydrogen or methyl or (CH2)q wherein q represents 0 to 4; Z represents oxygen, sulphur, NR , wherein R2 represents hydrogen or Cι-6 alkyl; Q represents (CH2)n wherein n represents 0 to 4, or CHR3 wherein R3 represents H, OH, Cι-6 alkyl, Cι-6 alkenyl, Cι-6 alkoxy or CH2CHR5 wherein R5 represents H, OH, lower alkyl (Cι-C4) or lower alkoxy (Cι-C4);
R4 represents hydrogen, Cι-Cι5 saturated or unsaturated aliphatic hydrocarbon groups in which any 1 to 6 hydrogen atoms may be substituted with the group independently selected from halogen, arylalkyl, arylalkenyl, heteroarylalkyl or heteroarylalkenyl having 1 to 2 hetero atoms selected from a group consisting of nitrogen, oxygen and sulphur atoms with option that any 1 to 3 hydrogen atoms on the ring in said arylalkyl, arylalkenyl, hetero arylalkenyl group may be substituted with lower alkyl (Cι-C4), lower perhalo alkyl (Cι-C4), cyano, hydroxyl, nitro, lower alkoxycarbonyl, halogen, lower alkoxy (Cι-C4), lower perhaloalkoxy (Cι-C4), unsubstituted amino, N-lower alkylamino (Cι-C4) or N- lower alkylamino carbonyl (Cι-C4); Re and R7 are independently selected from H, COOH, CH3, CONH2, NH2 or CH2NH2;
R8 andR are independently selected from a group consisting of hydrogen, lower alkyl (Cι-C ), trifluoromethyl, cyano, halogen, hydroxy, nitro, lower alkoxy (Cι-C4), amino or lower alkylamino.
6. The method according to claim 5 for treatment or prophylaxis of an animal or a human suffering from a disease or disorder of the respiratory, urinary and gastrointestinal systems, wherein the disease or disorder is mediated through the muscarinic receptors, comprising administering to said animal or human, a therapeutically effective amount of a compound having the structure of Formula II, and its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, polymorphs, or metabolites, wherein R8, R9, , W,X,Y,Z and Q are the same as defined for Formula I.
Formula II
(Formula I, Re=R7=H)
7. The method according to claim 5 wherein the disease or disorder is urinary incontinence, lower urinary tract symptoms (LUTS), bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary fibrosis, irritable bowel syndrome, obesity, diabetes, and gastrointestinal hyperkinesis.
8. The method according to claim 6 wherein the disease or disorder is urinary incontinence, lower urinary tract symptoms (LUTS), bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary fibrosis, irritable bowel syndrome, obesity, diabetes, and gastrointestinal hyperkinesis.
9. The method for treatment or prophylaxis of an animal or a human suffering from a disease or disorder of the respiratory, urinary, and gastrointestinal systems, wherein the disease or disorder is mediated through the muscarinic receptors, comprising administering to said animal or human, a therapeutically effective amount of the pharmaceutical composition according to claim 4.
10. The method according to claim 9 whrein the disease or disorder is urinary incontinence, lower urinary tract symptoms (LUTS), bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary fibrosis, irritable bowel syndrome, obesity, diabetes, and gastrointestinal hyperkineses.
11. A process of preparing a compound of Formula I
Formula I and its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs, metabolites, wherein;
W represents (CH2)P, where p represents 0 to 1 ; X represents an oxygen, sulphur, -NR or no atom; wherein R represents hydrogen or Ci-e alkyl; Y represents CHRiCO, wherein Ri represents hydrogen or methyl or (CH2)q wherein q represents 0 to 4; Z represents oxygen, sulphur, NR2, wherein R2 represents hydrogen or Cι-6 alkyl; Q represents (CH2)n wherein n represents 0 to 4, or CHR3 wherein R3 represents
H, OH, Ci-e alkyl, Cι-6 alkenyl, Cι-6 alkoxy or CH2CHR5 wherein R5 represents H, OH, lower alkyl (Cι-C4) or lower alkoxy (Cι-C4);
R4 represents hydrogen, -C15 saturated or unsaturated aliphatic hydrocarbon groups in which any 1 to 6 hydrogen atoms may be substituted with the group independently selected from halogen, arylalkyl, arylalkenyl, heteroarylalkyl or heteroarylalkenyl having 1 to 2 hetero atoms selected from a group consisting of nitrogen, oxygen and sulphur atoms with option that any 1 to 3 hydrogen atoms on the ring in said arylalkyl, arylalkenyl, hetero arylalkenyl group may be substituted with lower alkyl (Cι-C4), lower perhalo alkyl (Cι-C4), cyano, hydroxyl, nitro, lower alkoxycarbonyl, halogen, lower alkoxy (Cι-C4), lower perhaloalkoxy (Cι-C4), unsubstituted amino, N-lower alkylamino (Cι-C4) or N- lower alkylamino carbonyl (Cι-C4);
Re and R7 are independently selected from H, COOH, CH3, CONH2, NH2 or CH2NH2; and
R8 and R9 are independently selected from a group consisting of hydrogen, lower alkyl (Cι-C ), trifluoromethyl, cyano, halogen, hydroxy, nitro, lower alkoxy (Cι-C4), amino or lower alkylamino, comprising
a) condensing a compound of Formula III with a compound of Formula IN
Formula IV Formula III wherein W,X,Y,Z, Q, R , R6, R9, Rs have the same meanings as defined earlier forFormula I, to give a protected compound of Formula N, wherein P is a protecting group for an amino group,
Formula V
b) deprotecting the compound of Formula V in the presence of a deprotecting agent to give an unprotected intermediate of Formula VI wherein Re,R ,R8,R9, W,X,Y,Z,Q are the same as defined earlier, and
c) the intermediate of Formula VI is N-alkylated or benzylated with a suitable alkylating or benzylating agent, L- 4 wherein L is any leaving group, to give a compound of Formula I wherein R4, R8,R9,Re,R7, W,X,Y,Z,Q are the same as defined earlier.
12. The process according claim 11 wherein P is selected from the group consisting of benzyloxy and t-butyloxy carbonyl groups.
13. The process according to claim 11 wherein the reaction of a compound of Formula III with a compound of Formula IV to give a compound of Formula V is carried out in a suitable condensing agent which is selected from the group consisting of l-(3- dimethylamino propyl)-3-ethyl carbodiimide hydrochloride (EDC) and 1,8- diazabicyclo [5.4.0] undec-7-ene (DBU).
14. The process according to claim 11 wherein the reaction of a compound of Formula III with a compound of Formula IV to give a compound of Formula V is carried out in the presence of a suitable solvent selected from the group consisting of N,N dimethylformamide, dimethyl sulphoxide, toluene and xylene.
15. The process according to claim 11 wherein the reaction of a compound of Formula III with a compound of Formula IN is carried out at a temperature ranging from about 0- 140°C.
16. The process according to claim 11 wherein the deprotection of a compound of Formula N to give a compound of Formula NI is carried out with a deprotecting agent which is selected from the group consisting of palladium on carbon, trifluoroacetic acid and hydrochloric acid.
17. The process according to claim 11 wherein the deprotection of a compound of Formula N to give a compound of Formula NI is carried out in a suitable solvent selected from the group consisting of methanol, ethanol, tetrahydrofuran, and acetonitrile.
18. The process according to claim 11 wherein the Ν alkylation or benzylation of a compound of Formula NI to give a compound of Formula I is carried out with a suitable alkylating or benzylating agent, L-Rj, wherein L is any leaving group and R4 is the same as defined earlier.
EP02808274A 2002-12-23 2002-12-23 Xanthine derivatives as muscarinic receptor antagonists Withdrawn EP1590345A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2002/005589 WO2004056810A1 (en) 2002-12-23 2002-12-23 Xanthine derivatives as muscarinic receptor antagonists

Publications (1)

Publication Number Publication Date
EP1590345A1 true EP1590345A1 (en) 2005-11-02

Family

ID=32676694

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02808274A Withdrawn EP1590345A1 (en) 2002-12-23 2002-12-23 Xanthine derivatives as muscarinic receptor antagonists

Country Status (4)

Country Link
EP (1) EP1590345A1 (en)
AU (1) AU2002356369A1 (en)
CA (1) CA2511726A1 (en)
WO (1) WO2004056810A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0215801A (en) 2002-07-08 2005-05-10 Ranbaxy Lab Ltd 3,6-Disubstituted Azabicyclo [3.1.0] Hexane Derivatives Useful as Muscarinic Receptor Antagonists
US7517905B2 (en) 2003-04-09 2009-04-14 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EA009387B1 (en) 2003-04-11 2007-12-28 Рэнбакси Лабораториз Лимитед Azabicycloderivatives as muscarinic receptor antagonists
ATE419246T1 (en) * 2004-06-16 2009-01-15 Ranbaxy Lab Ltd XANTHINE DERIVATIVES SUITABLE AS ANTAGONISTS OF THE MUSCARINE RECEPTOR
WO2007039884A1 (en) 2005-10-05 2007-04-12 Ranbaxy Laboratories Limited 3 -azabicyclooctane derivatives as muscarinic receptor antagonists
US20090137623A1 (en) 2005-12-30 2009-05-28 Naresh Kumar Muscarinic receptor antagonists
AP2008004537A0 (en) 2005-12-30 2008-08-31 Ranbaxy Lab Ltd Muscarinic receptor antagonists
ES2425592T3 (en) 2007-04-24 2013-10-16 Theravance, Inc. Quaternary ammonium compounds useful as muscarinic receptor antagonists
US20090326004A1 (en) 2008-06-03 2009-12-31 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
EP2621902B1 (en) 2010-09-28 2017-04-12 Panacea Biotec Ltd 3-azabicyclo[3.1.0]hexane compounds useful for the treatment of cns disorders
KR20220034739A (en) 2019-05-31 2022-03-18 이케나 온콜로지, 인코포레이티드 TEAD inhibitors and uses thereof
KR20220030222A (en) 2019-05-31 2022-03-10 이케나 온콜로지, 인코포레이티드 TEAD inhibitors and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT8721978A0 (en) * 1987-09-21 1987-09-21 Angeli Inst Spa NEW TRICYCLIC AMIDE DERIVATIVES.
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
ES2165768B1 (en) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004056810A1 *

Also Published As

Publication number Publication date
WO2004056810A1 (en) 2004-07-08
AU2002356369A1 (en) 2004-07-14
CA2511726A1 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
US7399779B2 (en) 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonists
US7265147B2 (en) 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
US7446123B2 (en) Azabicyclo derivatives as muscarinic receptor antagonists
US7501443B2 (en) Flavaxate derivatives as muscarinic receptor antagonists
US7592359B2 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004056810A1 (en) Xanthine derivatives as muscarinic receptor antagonists
US20070010568A1 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EP1618091A1 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
US7560479B2 (en) 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
KR20060014373A (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
HK1079783B (en) 3,6-disubstituted azabicyclo 3.1.0 hexane derivatives useful as muscarinic receptor antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050725

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

17Q First examination report despatched

Effective date: 20080623

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: RANBAXY LABORATORIES LIMITED

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20031114

R18D Application deemed to be withdrawn (corrected)

Effective date: 20091114